📅 PUBMED DAILY TRIAGE — 2026-04-15

Window: 2026-04-14T09:00:00Z → 2026-04-15T09:00:00Z (CRDT) Topics scanned: 9 | Articles reviewed: ~90 (10/topic across 9 topics) | Candidates evaluated: ~90 High priority: 3 | Standard: 7 | Low/archive: 2 | Unsolicited finds: 1 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies (AML/MDS/CLL/MPN/Lymphoma)

TR-2026-04-15-001 / PMID 41981648 · In-situ polymerization-mediated glycan density measurement on extracellular vesicle surface for AML diagnosis · 8/10 · Novel microfluidic EV-glycan platform achieves AUC=0.904 in 47 clinical AML specimens; normalizes inter-patient variability for the first time in a blood-based AML diagnostic.

AI/ML in Clinical Diagnostics & Imaging

TR-2026-04-15-002 / PMID 41981644 · Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for lung cancer biomarker USE1 · 8/10 · AlphaFold3-guided aptamer + QD nanostructures achieve AUC=0.961 for USE1 lung cancer biomarker in 30 paired tissues; antibody-free, rapid, low-cost platform.

Novel Therapeutics / Precision Oncology (Underserved Population)

TR-2026-04-15-003 / PMID 41981524 · Real-world trends in NSCLC diagnosis, treatment, and survival in Vietnam · 8/10 · n=3,087 LMIC cohort documents OS nearly doubling (12→21.7 months, 2018–2024); targeted therapy adoption 7.7%→20.8%; provides rare LMIC real-world benchmark for precision oncology gains.

🟢⚪ STANDARD (4–7) — Top by Topic

Hematologic Malignancies

• TR-2026-04-15-004 / PMID 41981649 · TP53 rs1042522/rs1642785 in ALL, Brazilian Amazon · 6/10 · Genomics/Precision Medicine — Adds ALL genetic risk data for admixed Amazon population (underrepresented ancestry).

AI/ML in Clinical Diagnostics

• TR-2026-04-15-006 / PMID 41981562 · End-to-end explainable multilingual ICD-10 clinical coding AI · 5/10 · Diagnostics — Multilingual explainable NLP for automated clinical coding (English/Spanish/German).

Novel Therapeutics / Immunotherapy

• TR-2026-04-15-005 / PMID 41981680 · Autologous tumor-immune effusion cocultures for radiotherapy-immunotherapy profiling · 7/10 · Treatment Innovation — Patient-derived malignant effusion coculture enables personalized ex vivo radio-immunotherapy profiling; novel precision oncology approach.

GLP-1 / Cardiometabolic

• TR-2026-04-15-008 / PMID 41981378 · Gut-brain axis: link between T2D and Parkinson's disease · 4/10 · Drug Development — Review on GLP-1 signaling as shared T2D/Parkinson's pathway; borderline STANDARD.

Rare Diseases

• TR-2026-04-15-007 / PMID 41981708 · International Forum on Visceral Myopathy 2024 consensus · 6/10 · Rare diseases/VSCM — Ultra-rare ACTG2/MYH11 disease; international expert consensus on novel treatments and molecular targets.

CBC/ML Hematology (title-only)

• TR-2026-04-15-010 / PMID 41981480 · CBC/hematology AI study · 3/10 (title-only, abstract not retrieved) · Diagnostics — Top candidate from CBC/ML topic; scored conservatively.

Aging/Longevity (title-only)

• TR-2026-04-15-011 / PMID 41981721 · Aging/longevity biomarker study · 3/10 (title-only) · Public Health — Top candidate from aging/longevity topic.

💡 UNSOLICITED FINDS

TR-2026-04-15-009 / PMID 41981679 · Lineage-specific evolution and activity of R2 retrotransposons in animals · 6/10 · Genome Biology. Foundational phylogenomic study expanding R2 retrotransposon toolkit diversity; direct relevance to safe-harbor gene therapy insertion platform development. Collins lab (Addition Therapeutics COI declared). unsolicited_find=true.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 4
• Treatment Innovation: 2
• Genomics/Precision Medicine: 2
• Early Detection: 1 (overlapping with Diagnostics)
• Drug Development: 1
• Public Health: 1
• Other: 2

By evidence maturity:

• Validated: 3 (all HIGH)
• Exploratory: 9

By watchlist topic (reviewed / kept / highest score):

• Hematologic malignancies: 10 reviewed / 2 kept / 8
• Early cancer detection: 10 reviewed / 2 kept / 8 (via AI/ML topic)
• AI/ML diagnostics: 10 reviewed / 3 kept / 8
• Novel therapeutics/immunotherapy: 10 reviewed / 3 kept / 8
• GLP-1/cardiometabolic: 10 reviewed / 1 kept / 4
• CBC/ML hematology: 10 reviewed / 1 kept / 3 (title-only)
• Aging/longevity: 10 reviewed / 1 kept / 3 (title-only)
• Rare diseases: 10 reviewed / 1 kept / 6
• Sentinel scan: 10 reviewed / 1 kept (unsolicited) / 6

By source type: peer_reviewed 12 | preprint 0

Topics with zero 8+ articles this run:

• Early cancer detection (standalone) — top scored 6/10
• GLP-1/cardiometabolic — max 4/10
• CBC/ML hematology — 9th consecutive run with no HIGH; max 3/10 (title-only)
• Aging/longevity — max 3/10 (title-only)
• Rare diseases — max 6/10

🔧 RUN NOTES

• Window expansion: NOT triggered (>5 relevant records found in standard 24h window).
• Truncation: AI/ML diagnostics search returned 281 results; top 10 reviewed per protocol. Immunotherapy/targeted therapy: 399 results; top 10 reviewed. Sentinel scan: 1,891 results; top 10 reviewed. All truncations logged.
• Abstract retrieval limits: Due to XML batch size limits, abstracts for PMID 41981480 (CBC/ML) and PMID 41981721 (aging) were not retrieved; classified at title-only level (score capped at 3).
• CBC/ML hematology topic: 9th consecutive run with no HIGH-priority finds. This topic consistently returns sparse or low-signal daily additions; recommend reviewing watchlist query specificity or broadening scope.
• GLP-1/cardiometabolic: Strongest candidate is a narrative review (41981378, 4/10); no RCTs, trials, or large observational studies in this 24h window.
• Aging/longevity: Signal remains noisy; topic produces high volume of low-relevance results; max 3/10 today.
• Unsolicited find: PMID 41981679 (R2 retrotransposons, Genome Biology) flagged; Collins/UC Berkeley — gene therapy COI declared.
• Data quality: All HIGH records had abstract reviewed and PMID confirmed. Classification confidence = high for 10/12 records.